Sandra Garcet

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann et al. · Journal of the American Academy of Dermatology · 2018 · 328 citations · Full text

Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis

Saakshi Khattri, Patrick M. Brunner, Sandra Garcet et al. · Experimental Dermatology · 2016 · 214 citations · Full text

Allergy Medicine, Immunology, Skin Allergy +18

An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease

Benjamin Ungar, Sandra Garcet, Juana Gonzalez et al. · Journal of Investigative Dermatology · 2016 · 202 citations

Asthma, Inflammation, Allergy +10

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

Patrick M. Brunner, Ana B. Pavel, Saakshi Khattri et al. · Journal of Allergy and Clinical Immunology · 2018 · 188 citations · Full text

Inflammation, Allergy, Atopic Dermatitis +8

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis

Lisa Zhou, Alexandra Leonard, Ana B. Pavel et al. · Journal of Allergy and Clinical Immunology · 2019 · 134 citations · Full text

Molecular Phenotype, Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis +6